Abstract:Recent advances in high-resolution mass spectrometry-based proteomics have improved our understanding of lysine acetylation in proteins, including histones and non-histone proteins. Lysine acetylation, a reversible post-translational modification, is catalyzed by lysine acetyltransferases (KATs) and lysine deacetylases (KDACs). Proteins comprising evolutionarily conserved bromodomains (BRDs) recognize these acetylated lysine residues and consequently activate transcription. Lysine acetylation regulates almost all cellular processes, including transcription, cell cycle progression, and metabolic functions. Studies have reported the aberrant expression, translocation, and mutation of genes encoding lysine acetylation regulators in various cancers, including digestive tract cancers. These dysregulated lysine acetylation regulators contribute to the pathogenesis of digestive system cancers by modulating the expression and activity of cancer-related genes or pathways. Several inhibitors targeting KATs, KDACs, and BRDs are currently in preclinical trials and have demonstrated anti-cancer effects. Digestive tract cancers, including encompass esophageal, gastric, colorectal, liver, and pancreatic cancers, represent a group of heterogeneous malignancies. However, these cancers are typically diagnosed at an advanced stage owing to the lack of early symptoms and are consequently associated with poor 5-year survival rates. Thus, there is an urgent need to identify novel biomarkers for early detection, as well as to accurately predict the clinical outcomes and identify effective therapeutic targets for these malignancies. Although the role of lysine acetylation in digestive tract cancers remains unclear, further analysis could improve our understanding of its role in the pathogenesis of digestive tract cancers. This review aims to summarize the implications and pathogenic mechanisms of lysine acetylation dysregulation in digestive tract cancers, as well as its potential clinical applications.

A glimpse into novel acylations and their emerging role in regulating cancer metastasis

The role of novel protein acylations in cancer

Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification

Acetyl-CoA Metabolism As a Therapeutic Target for Cancer

Acetyl-CoA Regulates Lipid Metabolism and Histone Acetylation Modification in Cancer

Acetylation Control Of Cancer Cell Metabolism

Acetylation Control of Metabolic Enzymes in Cancer: an Updated Version

Targeting the acetylation signaling pathway in cancer therapy

Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects

The role of protein acetylation in carcinogenesis and targeted drug discovery

Impact of Acetylation on Tumor Metabolism

Lactylation in Cancer: Current Understanding and Challenges

Methylation Modification, Alternative Splicing, and Noncoding RNA Play a Role in Cancer Metastasis Through Epigenetic Regulation

Intricate effects of post-translational modifications in liver cancer: mechanisms to clinical applications

Acetylation in Tumor Immune Evasion Regulation

Disturbed mitochondrial acetylation in accordance with the availability of acetyl groups in hepatocellular carcinoma

Lysine 2-hydroxyisobutyrylation of NAT10 promotes cancer metastasis in an ac4C-dependent manner

Novel post-translational modifications of protein by metabolites with immune responses and immune-related molecules in cancer immunotherapy

Dysregulation of lysine acetylation in the pathogenesis of digestive tract cancers and its clinical applications

Protein post-translational modifications in the regulation of cancer hallmarks

Protein Lysine Acetylation Guards Metabolic Homeostasis to Fight Against Cancer